MYMD-1 Shows Promise in Reducing Drivers of IPF Inflammation, Fibrosis

MYMD-1 Shows Promise in Reducing Drivers of IPF Inflammation, Fibrosis

288360

MYMD-1 Shows Promise in Reducing Drivers of IPF Inflammation, Fibrosis

MYMD-1, MyMD Pharmaceuticals’ lead candidate for the treatment of several autoimmune and age-related disorders, showed promising efficacy in targeting the root causes of inflammation in idiopathic pulmonary fibrosis (IPF), according to data from a recent study. The therapy reduced the activity of molecules that are known drivers of inflammation and tissue scarring (fibrosis). Findings from the study, carried out by Eurofins Discovery, a global leader in food and pharmaceutical product testing, support the future development…

You must be logged in to read/download the full post.